



I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C., 20231, ON:

Date: 7/27/00

By: Franklin Dyer

Print Name: FRANKLIN DYER

DOCKET NO. 00211-US-NEW

#6 8/8/00 Today

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of)
MOYER, E., et al.) Examiner: Devi, S.
Serial No. 09/393,590) Art Unit: 1645
Filed: September 9, 1999)
For: STABLE LIQUID FORMU-)
LATIONS OF BOTULINUM)
TOXIN)

RESPONSE TO WRITTEN RESTRICTION REQUIREMENT


Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Requirement for Restriction mailed July 10, 2000 in the above-identified application, applicants hereby elect for examination, without traverse, the claims the Examiner has designated as Group I (claims 1-28) in the above-identified application for patent.

Since the elected claims are drawn to a product, the Examiner is requested to retain the additional method claims 29-53 as pending, in accordance with the provisions of MPEP 821.04.


Respectfully submitted,



Carol A. Stratford
Registration No. 34,444

July 27, 2000

Date



CUSTOMER NO: **21835**
ELAN PHARMACEUTICALS, INC.
800 Gateway Blvd.
South San Francisco, California 94080
Telephone: 650/877-7432